Intas Pharmaceuticals has signed an exclusive agreement with IntegriMedical, the developer of India’s first needle-free injection system, to introduce the technology for use in in vitro fertilisation and gynaecology treatments across the country.

The company said the partnership marks an important advancement in women’s health and reproductive care. By securing exclusive access to a first-of-its-kind needle-free injector for these therapies, Intas aims to transform both treatment delivery and patient experience, with a strong focus on comfort and confidence.

Under the agreement, Intas becomes the first company in India to offer IVF and gynaecology therapies using needle-free injections, establishing a new benchmark in patient-centric drug delivery. The collaboration is expected to significantly change how reproductive treatments are administered in clinical practice.

Leveraging IntegriMedical’s proprietary drug-delivery technology, Intas plans to reduce injection-related pain and anxiety while improving treatment adherence and overall patient satisfaction. Intas, in collaboration with IntegriMedical, will support the rollout of needle-free injection systems across IVF clinics and gynaecology centres nationwide.

India is among the fastest-growing IVF markets globally, with an estimated 300,000 to 350,000 treatment cycles conducted annually. This figure is projected to rise to around 500,000 to 600,000 cycles by 2027, translating into several million injections each year as part of IVF therapy. The integration of needle-free injection technology is expected to meaningfully improve the treatment experience for hundreds of thousands of women every year by reducing pain, anxiety, and treatment fatigue.

Commenting on the collaboration, Sarvesh Mutha, managing director of IntegriMedical, said the partnership brings the company’s vision to life by making treatments less intimidating and more humane. He added that the collaboration represents a significant step forward in patient-focused innovation in IVF and gynaecology care.

Durga P Satapathy, executive vice president at Intas, said the initiative goes beyond the introduction of new technology and is aimed at improving how patients experience care. He noted that IVF and gynaecology treatments can be physically and emotionally demanding, and the partnership reflects Intas’ commitment to making treatment journeys easier and more reassuring while setting new standards for patient-centric care in India.